Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,609.78
(
0.13%
)
US TECH 100
29,842.40
(
0.45%
)
Dow Jones
51,307.79
(
0.45%
)
Brent Oil
96.65
(
1.45%
)
Bitcoin
67,148.52
(
0.70%
)
News Focus
News Focus
Post# of 519116
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

tschussmann1

Send PM Follow Ignore
Followers 10
Posts 577
Boards Moderated 0
Alias Born 12/18/2010

tschussmann1

Re: Hoskuld post# 495841

Tuesday, 08/05/2025 7:53:32 PM

Tuesday, August 05, 2025 7:53:32 PM

Post# of 519116
A thought that I just had, but I expect Anavex has had for a while: can a precision drug be designed for each of the 4 genetic combinations, so that each group would be super responders for one drug. Assuming Blarcamesine is that for Sigmar1 Wild Type and COL24A1 Base, need 3 more drugs for the other 3 genetic combinations. Not sure if that is a "tweak" of Blarcamesine, or design from scratch. If Anavex could patent this space, that would be monumental.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News